United Therapeutics (NASDAQ:UTHR) is scheduled to be releasing its earnings data before the market opens on Tuesday, April 24th. Analysts expect United Therapeutics to post earnings of $3.48 per share for the quarter.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.59 by $0.30. The business had revenue of $464.70 million during the quarter, compared to the consensus estimate of $420.55 million. United Therapeutics had a return on equity of 24.41% and a net margin of 24.22%. United Therapeutics’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the company earned $4.12 earnings per share.
NASDAQ:UTHR opened at $114.06 on Monday. The company has a quick ratio of 3.01, a current ratio of 3.26 and a debt-to-equity ratio of 0.12. The stock has a market cap of $4,931.95, a P/E ratio of 10.47 and a beta of 1.34. United Therapeutics has a 52-week low of $106.30 and a 52-week high of $152.55.
In other news, CEO Martine A. Rothblatt sold 1,100 shares of the firm’s stock in a transaction that occurred on Thursday, March 22nd. The stock was sold at an average price of $110.01, for a total value of $121,011.00. Following the completion of the sale, the chief executive officer now directly owns 1,240 shares of the company’s stock, valued at $136,412.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 21,512 shares of the firm’s stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $112.55, for a total value of $2,421,175.60. Following the completion of the sale, the chief executive officer now directly owns 21,652 shares of the company’s stock, valued at $2,436,932.60. The disclosure for this sale can be found here. Insiders have sold 174,046 shares of company stock valued at $19,506,251 over the last three months. Insiders own 7.80% of the company’s stock.
Several research analysts recently commented on the company. Wedbush reissued an “outperform” rating and set a $232.00 price target (up from $213.00) on shares of United Therapeutics in a research report on Wednesday, December 27th. ValuEngine raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 26th. Oppenheimer increased their price target on United Therapeutics to $180.00 and gave the company an “outperform” rating in a research report on Friday, January 5th. Zacks Investment Research raised United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price target for the company in a research report on Monday, January 15th. Finally, Credit Suisse Group reissued an “underperform” rating and set a $118.00 price target on shares of United Therapeutics in a research report on Thursday, January 18th. Four research analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. United Therapeutics currently has a consensus rating of “Hold” and an average price target of $136.33.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/23/united-therapeutics-uthr-set-to-announce-earnings-on-tuesday.html.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.